2. Search Result
Search Result
Results for "

fibrotic lung

" in MedChemExpress (MCE) Product Catalog:

26

阻害剤およびアゴニスト

1

蛍光色素

1

ペプチド

1

阻害性抗体

5

天然物

2

同位体標識化合物

製品番号 製品名 Target 研究分野 構造式
  • HY-137561
    Bexotegrast
    3 Publications Verification

    PLN-74809

    		 Integrin Inflammation/Immunology
    Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
    Bexotegrast
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-121246
    Fluorofenidone
    1 Publications Verification

    AKF-PD

    		 ACSL Family NF-κB ERK TGF-beta/Smad Inflammation/Immunology Cancer
    Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
    Fluorofenidone
  • HY-132850
    Dazcapistat

    BLD-2660

    		 Proteasome Interleukin Related Infection Inflammation/Immunology
    Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis .
    Dazcapistat
  • HY-147243
    Ansornitinib

    ANG-3070

    		 VEGFR PDGFR Cardiovascular Disease Inflammation/Immunology
    Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
    Ansornitinib
  • HY-N1508
    Ecliptasaponin A

    		MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .
    Ecliptasaponin A
  • HY-N0671R
    Rhapontin (Standard)
    2 Publications Verification

    Rhaponiticin (Standard)

    		 Reference Standards Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin (Standard)
  • HY-178821
    ROCK2-IN-12

    		ROCK TGF-beta/Smad STAT Inflammation/Immunology
    ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC50 of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .
    ROCK2-IN-12
  • HY-143237
    ATX inhibitor 11

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC50 of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research .
    ATX inhibitor 11
  • HY-P4040
    Ac-D-DGla-LI-Cha-C

    		HCV Protease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .
    Ac-D-DGla-LI-Cha-C
  • HY-137561A
    Bexotegrast hydrochloride

    PLN-74809 hydrochloride

    		 Integrin Inflammation/Immunology
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
    Bexotegrast hydrochloride
  • HY-120107
    OAT-177

    		Parasite Inflammation/Immunology
    OAT-177 is a potent dual inhibitor targeting acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) with an IC50=14.2 nM for human AMCase and IC50=232 nM for human CHIT1. OAT-177 is promising for research of chronic inflammatory and fibrotic-related lung diseases such as asthma and idiopathic pulmonary fibrosis .
    OAT-177
  • HY-175033
    BRD4-IN-11

    		Epigenetic Reader Domain Phosphatase c-Myc Apoptosis Inflammation/Immunology
    BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .
    BRD4-IN-11
  • HY-169071S
    ATX-1905

    		Phosphodiesterase (PDE) Others
    ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
    ATX-1905
  • HY-143420
    ATX inhibitor 15

    		Phosphodiesterase (PDE) Inflammation/Immunology
    ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC50 of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model .
    ATX inhibitor 15
  • HY-119160
    TM5007

    		PAI-1 Inflammation/Immunology Cancer
    TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC50 of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .
    TM5007
  • HY-114366
    BC-1485

    		CXCR Others
    BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases α-SMA, BAL and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models .
    BC-1485
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-121246R
    Fluorofenidone (Standard)

    		ACSL Family Reference Standards NF-κB ERK TGF-beta/Smad Inflammation/Immunology
    Fluorofenidone (Standard) is the analytical standard of Fluorofenidone (AKF-PD) (HY-121246). This product is intended for research and analytical applications. Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
    Fluorofenidone (Standard)
  • HY-121246S
    Fluorofenidone-d3

    AKF-PD-d3

    		 Isotope-Labeled Compounds ACSL Family NF-κB ERK TGF-beta/Smad Inflammation/Immunology Cancer
    Fluorofenidone-d3 (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
    Fluorofenidone-d3
  • HY-N1508R
    Ecliptasaponin A (Standard)

    		Reference Standards MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
    Ecliptasaponin A (Standard)
  • HY-D3208
    oLOX

    		Fluorescent Dye Inflammation/Immunology
    oLOX is a fluorescent activity reporter. oLOX can be activated by lysyl oxidase family (LOXF) enzymes, which in turn releases a luciferin fluorescent product that reports LOXF enzyme activity. After oLOX is activated in in vitro fibrotic lung tissues, the fluorescence intensity increases, enabling real-time detection of fibrotic activity. oLOX can be used in studies related to pulmonary fibrosis .
    oLOX
  • HY-181741
    PI3K-001

    		Cathepsin Inflammation/Immunology
    PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
    PI3K-001
  • HY-N17317
    Isostrictiniin

    ITN

    		 Keap1-Nrf2 Heme Oxygenase (HO) JNK ERK p38 MAPK NF-κB Interleukin Related Metabolic Disease Inflammation/Immunology
    Isostrictiniin (ITN) is a polyphenolic compound isolated from Nymphaea candida. It upregulates the expression of Nrf2 and HO-1, while downregulating the expression of Keap1. Isostrictiniin reduces the phosphorylation levels of JNK, ERK1/2, p38, IκBα, and NF-κB p65. Isostrictiniin decreases the levels of pro-inflammatory mediators (IL-1β, IL-6, TNF-α, PGE2). Isostrictiniin alleviates LPS-induced acute lung injury and exerts protective effects against acute alcoholic liver injury. Additionally, isostrictiniin exhibits anti-inflammatory, antioxidant, and anti-fibrotic activities.
    Isostrictiniin
  • HY-P991950
    SHR-1906

    		TGF-beta/Smad Inflammation/Immunology
    SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    SHR-1906
  • HY-181431
    PXS 64

    		TGF-beta/Smad Inflammation/Immunology
    PXS 64, a mannose-6-phosphate (M6P) analogue. a lipophilic prodrug of PXS 25 (HY-181430). PXS 64 is an effective anti-fibrotic agent by inhibiting the activation of latent TGF-β1. PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts. PXS 64 reduces TGFβ-mediated collagen IV, fibronectin, MCP-1, and phospho-smad2 expression in kidney cells. PXS 64 reduces collagen deposition in dermal scar fibroblasts. PXS 64 can be used for the research of chronic kidney disease, idiopathic pulmonary fibrosis, scarring .
    PXS 64

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: